Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6

2002 ◽  
Vol 30 (9) ◽  
pp. 1987-1994 ◽  
Author(s):  
Alexander Geppert ◽  
Angela Steiner ◽  
Gerlinde Zorn ◽  
Georg Delle-Karth ◽  
Maria Koreny ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Interleukin 6 ◽  
Plasma Levels ◽  
High Plasma ◽  
Multiple Organ

Multiple Organ Failure and Refractory Cardiogenic Shock due to Venlafaxine Intoxication, Successfully Treated with Veno-Arterial Extracorporeal Life Support

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Painvin B ◽  
◽  
Le Balc’h P ◽  
Gicquel T ◽  
Camus C ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Life Support ◽  
Extracorporeal Life Support ◽  
Multiple Organ ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Prolonged Release ◽  
Refractory Cardiogenic Shock

Venlafaxine has critical side effects from arrhythmias to cardiogenic shock after toxic dose ingestion. We report a case of venlafaxine intoxication with Multiple Organ Failure (MOF) treated with Veno-Arterial Extracorporeal Life Support (VA-ECLS). A 60-year old male with a history of chronic depression ingested 72 tablets of prolonged-release venlafaxine hydrochloride 75 mg (total 5400 mg). Initial EKG showed broadened QRS complexes and Transthoracic Echocardiography (TTE) revealed diffuse ventricular hypokinesia with Left Ventricular Ejection Fraction (LVEF) of 15% for which dobutamine infusion was started. Due to persistent refractory cardiogenic shock and MOF, a Medos® Deltastream® VA-ECLS was surgically implanted in our intensive care unit. On day 1, toxicology analysis found plasma concentrations of venlafaxine 3.2mg/L and its metabolite desmethylvenlafaxine at 0.92 mg/L. At day 6, we performed a weaning trial, enabling ECLS removal. Motion defect of anteroseptal and inferolateral walls was also noticed. EKGs showed a shorten R wave in the anteroseptal territory leading to the potential diagnosis of underlying ischemic cardiomyopathy. The patient was extubated at day-10 and discharged for cardiology unit at day-17. At day-20, cardiac magnetic resonance imaging showed no sign of ischemia and TTE parameters were normalized. This is the first report of refractory cardiogenic shock and MOF due to venlafaxine intoxication treated with VA-ECLS. The main objective of ECLS is to restore cardiac output especially when ventricular failure is refractory to inotropes. Our experience suggests that MOF secondary to refractory cardiogenic shock should quickly prompt the implantation of a VA-ECLS in venlafaxine critical overdose.

Relationship between neopterin and granulocyte elastase plasma levels and the severity of multiple organ failure

1989 ◽  
Vol 17 (3) ◽  
pp. 221-226 ◽  
Author(s):  
RICHARD PACHER ◽  
HEINZ REDL ◽  
MICHAEL FRASS ◽  
DIETMAR H. PETZL ◽  
ERNST SCHUSTER ◽  
...  
Keyword(s):  
Multiple Organ Failure ◽  
Organ Failure ◽  
Plasma Levels ◽  
Multiple Organ ◽  
Granulocyte Elastase

scholarly journals Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions

2021 ◽  
Vol 5 (5) ◽  
pp. 260-267
Author(s):  
R.R. Samigullina ◽  
◽  
V.I. Mazurov ◽  
E.A. Trofimov ◽  
◽  
...  
Keyword(s):  
Multiple Organ Failure ◽  
Organ Failure ◽  
Rheumatic Diseases ◽  
Interleukin 6 ◽  
Multiple Organ ◽  
Genetically Engineered ◽  
High Dose ◽  
Inflammatory Rheumatic Diseases ◽  
Cytokine Storm ◽  
Complex Therapy

The rapid spread of a new coronavirus infection (COVID-19) requires innovative solutions, including tactics optimization in using genetically engineered and targeted drugs in patients with immuno-inflammatory rheumatic diseases (RD). The authors studied the characteristics of the complex therapy of immuno-inflammatory RD in the COVID-19 pandemic conditions, analyzed the COVID-19 course in patients with RD who received combined therapy with genetically engineered and basic synthetic anti-rheumatic drugs and were under follow-up from March 2020 to March 2021. The researchers found that synthetic basic (methotrexate, leflunomide, etc.), targeted synthetic (tofacitinib, baricitinib, apremilast) and biologic disease-modifying antirheumatic drugs used in the RD treatment, except high-dose glucocorticoids and anti-B cell drugs (rituximab), do not have a negative effect and are not associated with a severe COVID-19 course. The use of interleukin-6 (IL-6) inhibitors is the standard pathogenetic therapy for cytokine release syndrome in COVID-19. Proactive therapy with IL-6 inhibitors provides inhibition of systemic inflammation and contributes to the suppression of cytokine storm syndrome, preventing the development of multiple organ failure and fatal outcome. KEYWORDS: rheumatic diseases, cytokine storm, multiple organ failure, genetically engineered biological drugs, interleukin-6, COVID-19. FOR CITATION: Samigullina R.R., Mazurov V.I., Trofimov E.A. Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions. Russian Medical Inquiry. 2021;5(5):260–267 (in Russ.). DOI: 10.32364/2587-6821-2021- 5-5-260-267.

scholarly journals 201 Cardiogenic Shock and Multiple-Organ Failure

1993 ◽  
Vol 8 (S3) ◽  
pp. S120-S121
Author(s):  
N Oohama ◽  
I Yamanaka ◽  
S Imaki ◽  
T Ogawa
Keyword(s):  
Cardiogenic Shock ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Multiple Organ

RECOVERY FROM CARDIOGENIC SHOCK AND MULTIPLE ORGAN FAILURE WITH TCI-LVAS SUPPORT

ASAIO Journal ◽  
1999 ◽  
Vol 45 (2) ◽  
pp. 156
Author(s):  
S Kyo ◽  
T Koyanagi ◽  
H Asano ◽  
H Ouchi ◽  
H Tanabe ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Multiple Organ
Sign in / Sign up

Export Citation Format

Share Document